Shots:

• The P-III trial (ADVANCE-CIDP 1) evaluating Hyqvia as maintenance therapy vs PBO in a ratio (1:1) in 132 adult patients with CIDP and who had remained on a stable dosing regimen of intravenous immunoglobulin (IVIG) therapy for 3mos. prior to screening
• The results showed that the patients treated with Hyqvia achieved a significant reduction in relapse rate (9.7% vs 31.4%), respectively, lower probability of functional worsening rates (37.5% vs 54.4%), patients experienced longer time to relapse with the Kaplan–Meier curves separating early @~4wk., change in R-ODS centile scores −6.1 vs −0.9, respectively
• The safety profile was generally consistent with the existing EU summary of product characteristics. The therapy is currently under regulatory review in the US and EU for use as a maintenance therapy in adult patients with stable CIDP

Ref: Businesswire | Image: Takeda

Related News:- Takeda’s Hyqvia Receives the US FDA’s sBLA Approval for the Treatment of Childrens with Primary Immunodeficiency

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com